NCT06566508 Effectiveness of Asiaticoside as Intracanal Medication on Infectious/Inflammatory Contents in Teeth With Apical Periodontitis
| NCT ID | NCT06566508 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Mansoura University |
| Condition | Intracanal Medication |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2023-11-20 |
| Primary Completion | 2024-06-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 36 participants in total. It began in 2023-11-20 with a primary completion date of 2024-06-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to investigate \"clinically\" the effectiveness of Asiaticoside based intracanal medication compared to the commonly used intracanal medicaments (calcium hydroxide Ca(OH)2 and Ledermix) on the levels of bacteria and inflammatory cytokines in root canals and periradicular tissues of teeth with apical periodontitis.
Eligibility Criteria
Inclusion Criteria: • Single-rooted with pulp necrosis and apical periodontitis. Exclusion Criteria: Receiving antibiotic treatment within the preceding 3 months. * Reporting systemic disease. * Teeth that could not be isolated with rubber dam. * Teeth with periodontal pockets deeper than 3 mm.
Contact & Investigator
Amany Bader, prof
STUDY DIRECTOR
Faculty of Dentistry Mansoura University
Frequently Asked Questions
Who can join the NCT06566508 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 60 Years, studying Intracanal Medication. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06566508 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06566508 currently recruiting?
Yes, NCT06566508 is actively recruiting participants. Contact the research team at Salemamq@gmail.com for enrollment information.
Where is the NCT06566508 trial being conducted?
This trial is being conducted at Al Mansurah, Egypt.
Who is sponsoring the NCT06566508 clinical trial?
NCT06566508 is sponsored by Mansoura University. The principal investigator is Amany Bader, prof at Faculty of Dentistry Mansoura University. The trial plans to enroll 36 participants.